Haemonetics completes sale of whole blood assets to GVS for up to $67.8M

HAEMONETICS CORP

Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
Contingent consideration tied to three-year sales growth and other milestones.
Transaction closed on January 13, 2025, as previously disclosed in December 2024 8-K.
Assets divested are within the Blood Center business unit's whole blood segment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.